logo

Beam Therapeutics Inc. (BEAM)



Trade BEAM now with
  Date
  Headline
2/23/2021 8:48:46 AM Beam Therapeutics Completes Acquisition Of Guide Therapeutics
1/19/2021 6:51:01 AM Beam Agrees To Sell 2.79 Mln Shares To Certain Institutional Investors In Private Placement
11/13/2020 8:09:44 AM Beam Therapeutics To Present Preclinical Data From Its Liver-focused Programs At AASLD
11/10/2020 7:09:47 AM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $40 Price Target
8/13/2020 7:13:03 AM Wedbush Is Raising Beam Therapeutics Inc. (BEAM) FY21 Estimate To -1.93 From -2.13
8/13/2020 7:12:49 AM Wedbush Is Increasing Beam Therapeutics Inc. (BEAM) Q4 21 Estimate To -0.43 From -0.49
8/13/2020 7:12:35 AM Wedbush Is Increasing Beam Therapeutics Inc. (BEAM) Q3 21 Estimate To -0.41 From -0.46
8/13/2020 7:12:19 AM Wedbush Is Increasing Beam Therapeutics Inc. (BEAM) Q2 21 Estimate To -0.53 From -0.58
8/13/2020 7:12:03 AM Wedbush Is Increasing Beam Therapeutics Inc. (BEAM) Q1 21 Estimate To -0.56 From -0.61
8/13/2020 7:11:44 AM Wedbush Is Raising Beam Therapeutics Inc. (BEAM) FY20 Estimate To -2.37 From -2.48
8/13/2020 7:11:29 AM Wedbush Is Increasing Beam Therapeutics Inc. (BEAM) Q4 20 Estimate To -0.50 From -0.55
8/13/2020 7:11:14 AM Wedbush Is Raising Beam Therapeutics Inc. (BEAM) Q3 20 Estimate To -0.49 From -0.54
8/13/2020 7:10:27 AM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $32 Price Target
8/12/2020 6:40:33 AM Beam Therapeutics Q2 Loss Attributable To Stockholders $34.2 Mln Or $0.69/Shr Vs Loss $21.1 Mln Or $3.38/Shr Last Year